Cover Image

Introduction of a hexavalent vaccine containing acellular pertussis into the national immunization program for infants in Peru: a cost-consequence analysis of vaccination coverage

Abstract Background Infant vaccination coverage rates in Peru have declined in recent years, exacerbated by the COVID-19 pandemic. Introduction of the fully-liquid diphtheria, tetanus, and acellular pertussis (DTaP)-inactivated polio vaccine (IPV)-hepatitis B (HB)-Haemophilus influenzae type B (Hib)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Janice Seinfeld (Author), Alfredo Sobrevilla (Author), María Laura Rosales (Author), Mauricio Ibañez (Author), César Munayco (Author), Delia Ruiz (Author)
Format:	Book
Published:	BMC, 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru
by: Janice Seinfeld, et al.
Published: (2022)

Pertussis vaccine effectiveness following country-wide implementation of a hexavalent acellular pertussis immunization schedule in infants and children in Panama
by: Arlene E. Calvo, et al.
Published: (2024)

Should acellular pertussis vaccine be recommended to healthcare professionals?
by: José Cassio de Moraes, et al.
Published: (2013)

Should acellular pertussis vaccine be recommended to healthcare professionals?
by: José Cassio de Moraes, et al.

Vacina acelular contra pertússis para adolescentes Acellular pertussis vaccine for adolescents
by: Aroldo P. de Carvalho, et al.
Published: (2006)

How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?
by: Francisca Aguirre-Boza, et al.
Published: (2021)

Tetanus, Diphtheria, and Acellular Pertussis Vaccination Coverage Among Publicly Insured Pregnant Women, U.S., 2016-2019
by: Cheryl J. Isenhour, DVM, et al.
Published: (2023)

REACTOGENICITY OF ACELLULAR PERTUSSIS VACCINE AND THE POSSIBILITY OF ITS USE IN ELDER CHILDREN
by: M.G. Galitskaya, et al.
Published: (2008)

REACTOGENICITY OF ACELLULAR PERTUSSIS VACCINE AND THE POSSIBILITY OF ITS USE IN ELDER CHILDREN
by: M.G. Galitskaya, et al.
Published: (2008)

Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines
by: Timo Vesikari, et al.
Published: (2020)

Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States
by: Nicola P. Klein, et al.
Published: (2019)

Is it time to administer acellular pertussis vaccine to childbearing age/pregnant women in all areas using whole-cell pertussis vaccination schedule?
by: Abdoulreza Esteghamati, et al.
Published: (2021)

Safety testing of acellular pertussis vaccines: Use of animals and 3Rs alternatives
by: Marieke Hoonakker, et al.
Published: (2017)

Choosing from Whole Cell and Acellular Pertussis Vaccines- Dilemma for the Developing Countries
by: Muhammad Ali SYED
Published: (2017)

Use of acellular pertussis vaccines in the United States: can we do better?
by: Nicola P. Klein, et al.
Published: (2017)

Predictors of Tetanus-Diphtheria- Acellular Pertussis Vaccination Among Adults Receiving Tetanus Vaccine in the United States
by: Tracy L. Johns, et al.
Published: (2013)

Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness
by: Ousseny Zerbo, et al.
Published: (2022)

Risk of Brain Damage Following Pertussis Immunization with Whole-Cell cf Acellular Vaccines
by: J Gordon Millichap
Published: (2004)

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults
by: Geert Leroux-Roels, et al.
Published: (2018)

Attitudes of US Obstetricians Toward a Combined Tetanus-Diphtheria-Acellular Pertussis Vaccine for Adults
by: Sarah J. Clark, et al.
Published: (2006)

Factors associated with receipt of Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Tdap) in mothers who deliver preterm
by: Shetal I. Shah, et al.
Published: (2023)

Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
by: Peter Van den Steen, et al.
Published: (2023)

A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children
by: Takashi Nakano, et al.
Published: (2018)

Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults
by: Chukiat Sirivichayakul, et al.
Published: (2017)

Adverse Effects of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine in 6- to 7-Year-Old Children
by: Sung-Hsi Wei, et al.
Published: (2011)

Cost minimization analysis of a hexavalent vaccine in Argentina
by: Ignacio Olivera, et al.
Published: (2023)

Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India
by: Hitt J Sharma, et al.
Published: (2023)

Pertussis vaccination in Child Care Workers: room for improvement in coverage, policy and practice
by: Hope Kirsty, et al.
Published: (2012)

Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants
by: Yoshiyuki Tanaka, et al.
Published: (2017)

Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines
by: Nasamon Wanlapakorn, et al.
Published: (2024)

Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants
by: Hye-Kyung Cho, et al.
Published: (2021)

A worldwide overview for hexavalent vaccines and a glimpse into Turkiye's perspective
by: Metehan Özen, et al.
Published: (2024)

Serum sickness-like reaction after diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenzae type b conjugate (5-in-1 vaccine) vaccination: A case report
by: Wei-Yu Chen, et al.
Published: (2020)

Guillain Barré syndrome after combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine: A rare pediatric case report and review of literature
by: Meichen Pan, et al.
Published: (2023)

Inequalities in COVID-19 vaccination coverage in Peru: An ecological study
by: Ali Al-, et al.
Published: (2023)

Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine
by: Ignacio Olivera, et al.
Published: (2020)

New features of pertussis vaccination
by: A. P. Cherdantsev, et al.
Published: (2020)

Pertussis, anti-Bordetella pertussis toxin, vaccination, and clinical surveillance
by: Amnuay Kleebayoon, et al.
Published: (2023)

Pertussis, anti-Bordetella pertussis toxin, vaccination, and clinical surveillance
by: Amnuay Kleebayoon, et al.
Published: (2023)

PROTECTIVE EFFICACY OF PERTACTIN CONTAINING ACELLULAR DPT VACCINES
by: M.V. Fesenko, et al.
Published: (2008)